Please login to the form below
BI
This page shows the latest BI news and features for those working in and with pharma, biotech and healthcare.
Boehringer reports positive phase 2 data for spesolimab in generalised pustular psoriasis
Boehringer Ingelheim (BI) has reported positive results from its phase 2b trial of spesolimab, demonstrating that the anti-interleukin-36 receptor antibody can prevent flares in adolescent and adult patients with ... BI reports that there is a ‘high
Latest news
-
Moderna and CytomX to partner in deal worth up to 1.2bn
The partnership will also utilise the company’s Probody platform, along with Regeneron’s Veloci-Bi antibody development platform, and sees CytomX receive an upfront payment of $30m, as well as
-
Biogen and Eisai’s Alzheimer’s drug shown to slow memory decline in confirmatory study
The Clarity AD trial was a global phase 3 confirmatory placebo-controlled, double-blind, parallel-group, randomised clinical trial to assess a 10mg/kg bi-weekly dosage of lecanemab, an investigational
-
Regeneron and CytomX partner to create conditional bispecific cancer therapies
The partners will utilise CytomX’s Probody and Regeneron’s Veloci-Bi platforms, aiming to enable the development of investigational next-generation bispecific immunotherapies. ... This collaboration will enable Regeneron and CytomX to combine our
-
Boehringer Ingelheim enrols first patient in pulmonary fibrosis phase 3 trial
BI 1015550 reduced the rate of lung function decline in patients with IPF in a phase 2 trial. ... BI 1015550 was granted Breakthrough Therapy Designation by the US Food and Drug Administration in February 2022.
-
Biogen and Eisai’s lecanemab shows promise in confirmatory Alzheimer’s study
Eisai’s Clarity AD trial was a global phase 3 confirmatory placebo-controlled, double-blind, parallel-group, randomised clinical trial to assess a 10mg/kg bi-weekly dosage of lecanemab in
More from news
Approximately 4 fully matching, plus 106 partially matching documents found.
Latest Intelligence
-
The role of digital health technology tools in supporting medical adherence
A true bi-directional conversation will reveal risks for non-adherence that can be addressed in prescriber-patient discussions.
-
CAR-T cell therapy in oncology
Simultaneously targeting multiple tumour antigens using bi-specific chimeric antigen technology. Summary.
-
Putting the ovation into innovation: trends from ESMO
toxicity, including innovative bispecific monoclonal antibodies and Bi-specific T-cell engagers.
-
The ‘Million Hour Challenge’
Since the initiative launched, AstraZeneca has seen two consecutive increases in the bi-annual employee engagement survey, with 69% of AstraZeneca employees agreeing that ‘Together, we are making progress in our
-
Is it time we stopped talking about adherence?
attractive and valuable bi-product.
More from intelligence
Approximately 0 fully matching, plus 26 partially matching documents found.
Latest from PMHub
-
Listening to heads AND hearts in healthcare
We talk a lot about using emotions in healthcare communications, but not as much about the business intelligence(BI) behind it. ... What we don’t talk about as much is the business intelligence (BI) behind it.
-
Origins Insights wins the “Best Patient-Centric Approach” award at the BHBIA BOBI Awards 2021
patient voice and the critical role of BI in ensuring this is heard.
-
Havas Lynx Group
AbbVie. ALK. Astellas. AstraZeneca. Bayer. Boehringer Ingelheim. BI. BMS. Celgene. Sanofi Genzyme.
-
CSL
CSL are a healthcare specialist business intelligence consultancy. We help companies utilise tools like Power BI &Tableau.
-
New Leaf Technology Solutions Ltd
market in areas such as Incentive Compensation, KAM, Coaching, Collaboration platforms and BI sol.
More from PMHub
Approximately 1 fully matching, plus 12 partially matching documents found.
Subscribe to our email news alerts
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Sanofi's frexalimab shows promise in relapsing forms of MS
- Amgen reports positive results for Otezla in psoriatic arthritis
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- Seqera Labs and Genomics England partner to progress genomic research
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Supporting the most vulnerable: why pharma should get behind the NHS’ healthcare equity campaign
- Healing the Healers
- The (inevitable) digital transformation of Medical Affairs
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Pfizer’s RSV vaccine approved by FDA for older adults
No results were found
PMHub
Page & Page and Partners
For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...
Latest intelligence
- Healing the Healers
- Because if we do not heal the healers, who is going to heal us?...
- The (inevitable) digital transformation of Medical Affairs
- It’s not a question of ‘if,’ it’s a question of ‘when.’...
- Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment
- Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts...
